Some studies suggest a potential link, while others provide limited evidence
"And their real-world effectiveness is about half of what's been reported in the clinical trials, probably because most people stop taking them, often for a combination of reasons including side effects, cost, and access," say Dr
Summary: GLP-1 receptor agonists produce modest reductions in total cholesterol, LDL cholesterol, and triglycerides, but are not licensed or recommended as primary treatments for dyslipidaemia
Month 1 (weeks 1-4) requires small frequent meals every 3 hours focusing on bland, easy-to-digest foods
The overall heterogeneity for renal outcome was I 2 = 42.3% (95% uncertainty intervals, 0 and 68.0%) (moderate) (Additional file 1: Table S3) with no evidence of publication bias
18), S440S448 (2007)